S2. PFS by platinum-sensitivity in ovarian cancer patients treated with fluzoparib ≥120 mg/d.

Platinum-based therapy	End point	120 mg qd	60 mg bid	160 mg qd	80 mg bid	100 mg bid	150 mg bid	200 mg bid	Total
PFS, progression-free survival; /, not applicable; −, not reached.
First line platinum-sensitive and last course platinum-sensitive	Total subjects (N)	1	1	0	1	6	2	0	11
	Efficacy evaluable subjects (n)	1	1	0	1	5	2	0	10
	mPFS (95% CI) based on total subjects (month)	7.4	9.3	/	−	−	−	/	9.3 (7.2−9.3)
	mPFS (95% CI) based on efficacy evaluable subjects (month)	7.4	9.3	/	−	−	−	/	9.3 (7.2−9.3)
First line platinum-sensitive and last course platinum resistant	Total subjects (N)	0	0	1	4	0	4	1	10
	Efficacy evaluable subjects (n)	0	0	1	3	0	3	1	8
	mPFS (95% CI) based on total subjects (month)	/	/	8.3	3.6	/	−	−	3.6 (1.7−8.3)
	mPFS (95% CI) based on efficacy evaluable subjects (month)	/	/	8.3	3.6	/	−	−	3.6 (1.7−8.3)
First line platinum-sensitive and last course platinum refractory	Total subjects (N)	0	1	0	2	4	2	0	9
	Efficacy evaluable subjects (n)	0	1	0	2	4	2	0	9
	mPFS (95% CI) based on total subjects (month)	/	−	/	−	−	1.8	/	1.9 (1.7−1.9)
	mPFS (95% CI) based on efficacy evaluable subjects (month)	/	−	/	−	−	1.8	/	1.9 (1.7−1.9)
First line platinum-resistant or refractory	Total subjects (N)	0	0	0	4	2	6	1	13
	Efficacy evaluable subjects (n)	0	0	0	2	2	3	1	8
	mPFS (95% CI) based on total subjects (month)	/	/	/	1.8	−	−	1.7	−
	mPFS (95% CI) based on efficacy evaluable subjects (month)	/	/	/	1.8	−	−	1.7	−
Overall	Subjects (N)	1	2	1	11	12	14	2	43
	Efficacy evaluable subjects (n)	1	2	1	8	11	10	2	35
	mPFS (95% CI) based on total subjects (month)	7.4	9.3	6.3	−	−	1.9	−	7.2 (1.8−9.3)
	mPFS (95% CI) based on efficacy evaluable subjects (month)	7.4	9.3	6.3	−	−	1.9	−	7.2 (1.8−9.3)